Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
2.
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Am J Hematol
; 97(3): 329-337, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981570
3.
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Am J Hematol
; 97(11): 1443-1452, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054614
4.
Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.
Curr Treat Options Oncol
; 21(4): 34, 2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32318829
5.
Utility of protocol kidney biopsies for de novo donor-specific antibodies.
Am J Transplant
; 17(12): 3210-3218, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28805293
6.
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia.
J Immunother Cancer
; 12(2)2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418394
7.
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
Cancer Res Commun
; 4(3): 671-681, 2024 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38391202
8.
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Cancer Cell
; 42(4): 605-622.e11, 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38458188
9.
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.
Nat Commun
; 15(1): 1821, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418901
10.
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion.
Cancer Immunol Res
; 2023 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163233
11.
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion.
Cancer Immunol Res
; : OF1-OF18, 2023 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285177
12.
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Lancet Haematol
; 9(5): e350-e360, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35483396
13.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
J Clin Oncol
; 40(33): 3848-3857, 2022 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35704787
14.
Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Front Immunol
; 12: 659625, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33912187
15.
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
Leuk Lymphoma
; 62(14): 3402-3410, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380367
16.
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Lancet Haematol
; 8(8): e552-e561, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329576
17.
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Nat Commun
; 12(1): 6071, 2021 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34663807
18.
Maintenance Therapy in AML.
Front Oncol
; 10: 619085, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604298
19.
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
J Immunother Cancer
; 7(1): 70, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30871628
20.
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Clin Cancer Res
; 24(1): 189-196, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28972044